OCULAR THERAPEUTIX, INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
OCULAR THERAPEUTIX, INC (OCUL) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $7.85 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-05
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $7.85M, a 68.46% decline year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$12.38M.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $11.32M.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $11.76M, a 31.25% increase year-over-year.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $35.57M.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$38.57M.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$38.59M.
- OCULAR THERAPEUTIX, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$387.00K, a 110.15% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $7.85M 10-Q · filed 2017-05-05 | -$4.53M derived: sum of 2 quarters · filed 2017-05-05 | $6.78M derived: sum of 3 quarters · filed 2017-05-05 | $18.54M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | -$12.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$1.06M derived: sum of 2 quarters · filed 2017-03-10 | $10.70M derived: sum of 3 quarters · filed 2017-03-10 | $35.57M 10-K · filed 2017-03-10 |
| 2016-09-30 | $11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $23.07M derived: sum of 2 quarters · filed 2016-11-09 | $47.95M 10-Q · filed 2016-11-09 | $45.86M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-06-30 | $11.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $36.63M 10-Q · filed 2016-08-09 | $34.54M derived: sum of 3 quarters · filed 2017-05-05 | $6.96M derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-03-31 | $24.87M 10-Q · filed 2017-05-05 | $22.79M derived: sum of 2 quarters · filed 2017-05-05 | -$4.80M derived: sum of 3 quarters · filed 2017-05-05 | $4.16M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | -$2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$29.67M derived: sum of 2 quarters · filed 2017-03-10 | -$20.71M derived: sum of 3 quarters · filed 2017-03-10 | -$38.57M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$27.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$18.63M derived: sum of 2 quarters · filed 2016-11-09 | -$36.48M 10-Q · filed 2016-11-09 | -$74.25M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$8.90M 10-Q · filed 2016-08-09 | -$46.66M derived: sum of 3 quarters · filed 2017-03-10 | -$46.94M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | -$17.85M 10-Q · filed 2016-05-10 | -$55.62M derived: sum of 2 quarters · filed 2017-03-10 | -$55.90M derived: sum of 3 quarters · filed 2017-03-10 | -$56.14M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$37.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$38.04M derived: sum of 2 quarters · filed 2017-03-10 | -$38.29M derived: sum of 3 quarters · filed 2017-03-10 | -$38.59M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$522.00K derived: sum of 2 quarters · filed 2015-11-10 | -$819.00K 10-Q · filed 2015-11-10 | -$1.02M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | -$248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$545.00K 10-Q · filed 2015-08-10 | -$751.00K derived: sum of 3 quarters · filed 2016-03-10 | -$860.00K derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | -$297.00K 10-Q · filed 2015-05-15 | -$503.00K derived: sum of 2 quarters · filed 2016-03-10 | -$612.00K derived: sum of 3 quarters · filed 2016-03-10 | |
| 2013-12-31 | -$206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$315.00K derived: sum of 2 quarters · filed 2016-03-10 | -$387.00K 10-K · filed 2016-03-10 | |
| 2013-09-30 | -$109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$181.00K 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$72.00K 10-Q · filed 2014-08-29 | |||
| 2012-12-31 | $3.81M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |